Regency Capital Management Inc. DE Has $138,000 Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Regency Capital Management Inc. DE trimmed its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 9.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,000 shares of the company’s stock after selling 1,000 shares during the period. Regency Capital Management Inc. DE’s holdings in Day One Biopharmaceuticals were worth $138,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its holdings in Day One Biopharmaceuticals by 28.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after purchasing an additional 472,654 shares during the last quarter. Parkman Healthcare Partners LLC lifted its stake in shares of Day One Biopharmaceuticals by 34.2% during the 4th quarter. Parkman Healthcare Partners LLC now owns 625,749 shares of the company’s stock worth $9,136,000 after buying an additional 159,341 shares during the last quarter. Braidwell LP boosted its holdings in shares of Day One Biopharmaceuticals by 13.5% during the 4th quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock worth $61,547,000 after buying an additional 500,000 shares during the period. Janus Henderson Group PLC grew its stake in Day One Biopharmaceuticals by 19.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,032,384 shares of the company’s stock valued at $33,575,000 after buying an additional 336,281 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in Day One Biopharmaceuticals by 77.7% in the 4th quarter. Wellington Management Group LLP now owns 208,969 shares of the company’s stock valued at $3,051,000 after acquiring an additional 91,393 shares during the period. 87.95% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on DAWN. Piper Sandler restated an “overweight” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Monday, July 8th. Wedbush restated an “outperform” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and increased their price objective for the stock from $11.00 to $24.00 in a research report on Thursday, August 1st. JPMorgan Chase & Co. reduced their target price on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, August 1st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Day One Biopharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.71.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 10,681 shares of the company’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $149,534.00. Following the completion of the sale, the chief executive officer now directly owns 98,932 shares in the company, valued at $1,385,048. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total value of $426,600.00. Following the transaction, the insider now owns 1,097,535 shares in the company, valued at $15,606,947.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jeremy Bender sold 10,681 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $149,534.00. Following the completion of the transaction, the chief executive officer now directly owns 98,932 shares of the company’s stock, valued at approximately $1,385,048. The disclosure for this sale can be found here. Insiders have sold 68,748 shares of company stock valued at $1,009,272 over the last three months. 8.40% of the stock is owned by insiders.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ DAWN opened at $13.93 on Tuesday. The stock has a market capitalization of $1.22 billion, a P/E ratio of -5.55 and a beta of -1.51. The stock’s fifty day moving average is $14.12 and its 200 day moving average is $14.48. Day One Biopharmaceuticals, Inc. has a 52 week low of $9.67 and a 52 week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Tuesday, July 30th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.70. The firm had revenue of $8.19 million during the quarter, compared to the consensus estimate of $0.90 million. Equities research analysts forecast that Day One Biopharmaceuticals, Inc. will post -1.68 earnings per share for the current year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.